Aldeyra Therapeutics

ALDX · Nasdaq · United States

Share price · ALDX

$0.67-0.88 (-56.70%) 3M

close as of 2026-11-18 · 24h delayed · vol 528K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026-15.0%

    Nothing announced by ALDX that day or the session before.

  2. 14 Oct 2026-12.2%

    Nothing announced by ALDX that day or the session before.

  3. 5 Oct 2026-21.1%

    Nothing announced by ALDX that day or the session before.

  4. 2 Oct 2026-9.3%

    Nothing announced by ALDX that day or the session before.

  5. 29 Sep 2026+13.8%
  6. 24 Sep 2026-9.6%

    Nothing announced by ALDX that day or the session before.

  7. 1 Jul 2026+14.1%

    Nothing announced by ALDX that day or the session before.

  8. 29 Jun 2026+12.0%

    Nothing announced by ALDX that day or the session before.

  9. 23 Mar 2026+23.2%

    Nothing announced by ALDX that day or the session before.

  10. 19 Mar 2026+28.9%

    Nothing announced by ALDX that day or the session before.

Share of unusual movement by asset

For each asset, the share of ALDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
reproxalap
events and moves
955%
Other company news (earnings, financing, releases naming no asset)—3%
Sessions with no dated event—41%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Reactive aldehyde species (RASP)Small molecule
Dry Eye DiseaseAllergic Conjunctivitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 March 2026Complete response letterreproxalapFDA issues third complete response letter for reproxalap in dry eye disease
US, FDA · Aldeyra Therapeutics · Source ↗
17 July 2025Filing acceptedreproxalapFDA accepts the resubmitted reproxalap NDA (PDUFA December 16, 2025)
US, FDA · Source ↗
5 May 2025Topline resultreproxalapDry eye chamber trial (NCT06493604) Phase 3 met its primary endpoint
Aldeyra Therapeutics, Inc. · Source ↗
3 April 2025Complete response letterreproxalapFDA issues second complete response letter for the resubmitted reproxalap NDA
US, FDA · Aldeyra Therapeutics, Inc. · Source ↗
October 2024Filing submittedreproxalapReproxalap NDA resubmitted after the 2023 complete response letter
US, FDA · Source ↗
8 August 2024Topline resultreproxalapDry eye chamber trial (NCT06389214) Phase 3 met its primary endpoint
Aldeyra Therapeutics, Inc. · Source ↗
November 2023Complete response letterreproxalapFDA issues first complete response letter for reproxalap in dry eye disease
US, FDA · Aldeyra Therapeutics, Inc. · Source ↗
December 2022Filing submittedreproxalapReproxalap NDA submitted
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$1.8M$41M$3.8M-$4.1M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$3.5M$45M$5.5M-$4.6M operating cash flowreport ↗
2026-Q1—$2.4M$65M$3.5M-$5.1M operating cash flowreport ↗
2025-Q3—$5.4M$59M+ $16M short-term inv.$7.7M-$7.0M operating cash flowreport ↗
2025-Q2—$8.5M$41M+ $41M short-term inv.$9.8M-$8.6M operating cash flowreport ↗
2025-Q1—$7.4M$50M+ $40M short-term inv.$9.9M-$12M operating cash flowreport ↗
2024-Q3—$12M$68M+ $45M short-term inv.$15M-$8.0M operating cash flowreport ↗
2024-Q2—$15M$71M+ $49M short-term inv.$17M-$13M operating cash flowreport ↗
2024-Q1—$6.2M$102M+ $31M short-term inv.$8.1M-$10.0M operating cash flowreport ↗
2023-Q3—$7.0M$143M+ $0 short-term inv.$8.2M-$8.0M operating cash flowreport ↗
2023-Q2—$7.0M$152M+ $0 short-term inv.$9.0M-$13M operating cash flowreport ↗
2023-Q1—$11M$165M+ $0 short-term inv.$16M-$9.4M operating cash flowreport ↗
2022-Q3—$12M$129M+ $57M short-term inv.$15M-$13M operating cash flowreport ↗
2022-Q2—$15M$121M+ $76M short-term inv.$18M-$20M operating cash flowreport ↗
2022-Q1—$12M$159M+ $58M short-term inv.$17M-$13M operating cash flowreport ↗
2021-Q3—$13M$241M$16M-$8.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$26M$70M+ $0 short-term inv.$8.5M-$33M operating cash flowreport ↗

Aldeyra Therapeutics reported no disclosed revenue for FY2025, with R&D spend of $25.66M, down 46.8% YoY. Cash and equivalents totaled $70.04M, and the company reported a net loss of $33.85M, with quarterly net burn of $33.85M.

During the period, the company resubmitted the reproxalap NDA for dry eye disease on June 17, 2025; the FDA subsequently requested that the field trial be submitted, extending the PDUFA target action date to March 16, 2026. AbbVie had not exercised its exclusive option as of February 27, 2026. For ADX-2191, the FDA agreed under a Special Protocol Assessment that a positive randomized trial could support NDA resubmission for primary vitreoretinal lymphoma, with top-line results expected in 2026; a Phase 2/3 trial in retinitis pigmentosa is planned for the first half of 2026. Trials of ADX-248 and ADX-246 are expected to begin in 2026 and 2027, respectively.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$48M$55M+ $47M short-term inv.$14M-$43M operating cash flowreport ↗
2023-FY—$29M$143M+ $0 short-term inv.$9.4M-$30M operating cash flowreport ↗
2022-FY—$47M$144M+ $30M short-term inv.$16M-$57M operating cash flowreport ↗
2021-FY—$45M$230M+ $0 short-term inv.$14M-$43M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($664K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12DEPTULA-HICKS DARLENE M · directorOpen-market purchase7,500$0.65$5KForm 4
2026-11-11DOUGLAS RICHARD · directorOpen-market purchase200,000$0.64$129KForm 4
2026-11-11Alfieri Michael · Principal Financial OfficerOpen-market purchase10,000$0.65$7KForm 4
2026-06-09DEPTULA-HICKS DARLENE M · directorAward / grant (derivative)84,557——Form 4
2026-06-09Bronstein Ben · directorAward / grant (derivative)70,000——Form 4
2026-06-09Walker Neal · directorAward / grant (derivative)70,000——Form 4
2026-06-09Clark William D · directorAward / grant (derivative)70,000——Form 4
2026-06-09Phillips Gary M. · directorAward / grant (derivative)70,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 124 reporting institutions held 37.3M shares ($60.7M, 61.8% of shares outstanding).

#InstitutionSharesValue
1Knoll Capital Management, LLC5,475,516$9.3M
2BlackRock, Inc.3,763,887$6.4M
3AQR CAPITAL MANAGEMENT LLC2,829,875$4.8M
4VANGUARD CAPITAL MANAGEMENT LLC2,363,742$4.0M
5KINGDON CAPITAL MANAGEMENT, L.L.C.2,152,315$3.6M
6683 Capital Management, LLC1,500,000$2.5M
7D. E. Shaw & Co., Inc.1,403,990$2.4M
8GEODE CAPITAL MANAGEMENT, LLC1,251,652$2.1M
9STATE STREET CORP1,124,710$1.9M
10MILLENNIUM MANAGEMENT LLC995,243$1.7M
11JANE STREET GROUP, LLC968,891$1.6M
12ARDSLEY ADVISORY PARTNERS LP950,000$1.6M
13RENAISSANCE TECHNOLOGIES LLC863,187$1.5M
14VANGUARD PORTFOLIO MANAGEMENT LLC807,778$1.4M
15JACOBS LEVY EQUITY MANAGEMENT, INC796,816$1.3M